Genelux vs Alaunos Therapeutics
GNLX and TCRT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GNLX and TCRT compare
Genelux is the larger company, worth 21 times as much as Alaunos Therapeutics ($90.5M against $4.2M).
Genelux scores higher on the StockData Score (5 against 4 for Alaunos Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GNLX | TCRT |
|---|---|---|
| Size and price | ||
| Market cap | $90.5M | $4.2M |
| Share price | $2.00 | $1.66 |
| Change, 1 year | −62.4% | −44.1% |
| Change, 5 years | – | −99.2% |
| Beta (5Y) | 0.73 | −2.45 |
| Employees | – | 1 |
| StockData Score | ||
| Total score | 5 (better) | 4 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 1406× |
| P/B | 5.6× (better) | 6.5× |
| FCF yield | −31.7% | – |
| Growth | ||
| Revenue growth (TTM) | – | −50.0% |
| Profitability | ||
| Operating margin | – | −135267% |
| Net margin | – | −133667% |
| Return on equity | −178% (better) | −186% |
| Return on invested capital | – | −489% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 2.39 (better) | 0.77 |
| Altman Z-score | −14.83 (better) | −861.74 |
| Piotroski F-score | 1 | 3 (better) |
| Dividends and buybacks | ||
| Buyback yield | −20.8% | – |
| Shareholder yield | −20.8% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 21.7% | 3.6% |
| Held by insiders | 7.7% | 69.8% |
| Insider net buying, 12 months | −$341K | – |
| Short interest, % of float | 10.9% | 24.0% |
Go deeper
- GNLX stock overview
- GNLX income statement
- GNLX valuation and score
- TCRT stock overview
- TCRT income statement
- TCRT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.